Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Background: The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. Methods: We eval...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-09-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396420303388 |
| id |
doaj-e0df1f7dff7f4d3890cfd8c1b6d74e95 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Anne Fröhlich Judith Sirokay Simon Fietz Timo J. Vogt Jörn Dietrich Romina Zarbl Mike Florin Pia Kuster Gonzalo Saavedra Susana Ramírez Valladolid Friederike Hoffmann Lukas Flatz Sandra S. Ring Carsten Golletz Torsten Pietsch Sebastian Strieth Peter Brossart Gerrit H. Gielen Glen Kristiansen Friedrich Bootz Jennifer Landsberg Dimo Dietrich |
| spellingShingle |
Anne Fröhlich Judith Sirokay Simon Fietz Timo J. Vogt Jörn Dietrich Romina Zarbl Mike Florin Pia Kuster Gonzalo Saavedra Susana Ramírez Valladolid Friederike Hoffmann Lukas Flatz Sandra S. Ring Carsten Golletz Torsten Pietsch Sebastian Strieth Peter Brossart Gerrit H. Gielen Glen Kristiansen Friedrich Bootz Jennifer Landsberg Dimo Dietrich Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma EBioMedicine LAG3 DNA Methylation Melanoma Predictive Biomarker Immunotherapy |
| author_facet |
Anne Fröhlich Judith Sirokay Simon Fietz Timo J. Vogt Jörn Dietrich Romina Zarbl Mike Florin Pia Kuster Gonzalo Saavedra Susana Ramírez Valladolid Friederike Hoffmann Lukas Flatz Sandra S. Ring Carsten Golletz Torsten Pietsch Sebastian Strieth Peter Brossart Gerrit H. Gielen Glen Kristiansen Friedrich Bootz Jennifer Landsberg Dimo Dietrich |
| author_sort |
Anne Fröhlich |
| title |
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma |
| title_short |
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma |
| title_full |
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma |
| title_fullStr |
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma |
| title_full_unstemmed |
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma |
| title_sort |
molecular, clinicopathological, and immune correlates of lag3 promoter dna methylation in melanoma |
| publisher |
Elsevier |
| series |
EBioMedicine |
| issn |
2352-3964 |
| publishDate |
2020-09-01 |
| description |
Background: The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. Methods: We evaluated LAG3 promoter and gene body methylation in a cohort of N = 470 melanoma patients obtained from The Cancer Genome Atlas (TCGA cohort), an independent cohort of N = 120 patients from the University Hospital Bonn, and in subsets of peripheral blood leukocytes, melanocytes, and melanoma cell lines. We validated the association of LAG3 methylation with mRNA expression in vitro in the melanoma cell line A375 treated with the hypomethylating agent 5-azacytidine and stimulated with interferon-γ. Finally, we investigated correlations between LAG3 methylation and progression-free survival in patients treated with immune checkpoint blockade (ICB cohort, N = 118). Findings: Depending on the analysed locus (promoter, gene body) we found region-dependent significant LAG3 methylation differences between monocytes, B cells, CD8+ and CD4+ T cells, regulatory T cells, melanocytes, and melanoma cell lines. In tumor tissues, methylation correlated significantly with LAG3 mRNA expression, immune cell infiltrates (histopathologic lymphocyte score and RNA-Seq signatures of distinct immune infiltrates), and an interferon-γ signature. Finally, LAG3 methylation was associated with overall survival in the TCGA cohort and progression-free survival in the ICB cohort. We detected basal LAG3 mRNA expression in the melanoma cell A375 and an interferon-γ inducible expression after demethylation with 5-azacytidine. Interpretation: Our study points towards an epigenetic regulation of LAG3 via promoter methylation and suggests a prognostic and predictive significance of LAG3 methylation in melanoma. Our results give insight in the tumor cell-intrinsic transcriptional regulation of LAG3 in melanoma. In perspective, our results might pave the way for investigating LAG3 methylation as a predictive biomarker for response to anti-LAG3 immune checkpoint blockage. Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgements section. |
| topic |
LAG3 DNA Methylation Melanoma Predictive Biomarker Immunotherapy |
| url |
http://www.sciencedirect.com/science/article/pii/S2352396420303388 |
| work_keys_str_mv |
AT annefrohlich molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT judithsirokay molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT simonfietz molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT timojvogt molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT jorndietrich molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT rominazarbl molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT mikeflorin molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT piakuster molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT gonzalosaavedra molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT susanaramirezvalladolid molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT friederikehoffmann molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT lukasflatz molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT sandrasring molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT carstengolletz molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT torstenpietsch molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT sebastianstrieth molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT peterbrossart molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT gerrithgielen molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT glenkristiansen molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT friedrichbootz molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT jenniferlandsberg molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma AT dimodietrich molecularclinicopathologicalandimmunecorrelatesoflag3promoterdnamethylationinmelanoma |
| _version_ |
1724530645152038912 |
| spelling |
doaj-e0df1f7dff7f4d3890cfd8c1b6d74e952020-11-25T03:41:17ZengElsevierEBioMedicine2352-39642020-09-0159102962Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanomaAnne Fröhlich0Judith Sirokay1Simon Fietz2Timo J. Vogt3Jörn Dietrich4Romina Zarbl5Mike Florin6Pia Kuster7Gonzalo Saavedra8Susana Ramírez Valladolid9Friederike Hoffmann10Lukas Flatz11Sandra S. Ring12Carsten Golletz13Torsten Pietsch14Sebastian Strieth15Peter Brossart16Gerrit H. Gielen17Glen Kristiansen18Friedrich Bootz19Jennifer Landsberg20Dimo Dietrich21Department of Dermatology and Allergy, University of Bonn, Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, Germany; Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, Germany; Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, Germany; Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, Germany; Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, GermanyInstitute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland.; Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Department of Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, SwitzerlandInstitute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland.; Microbiology and Immunology PhD Program, University of Zurich, Zurich, SwitzerlandInstitute of Pathology, University Hospital Bonn, Bonn, GermanyInstitute of Neuropathology, University Hospital Bonn, Bonn, GermanyDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, GermanyInstitute of Neuropathology, University Hospital Bonn, Bonn, GermanyInstitute of Pathology, University Hospital Bonn, Bonn, GermanyDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, GermanyDepartment of Dermatology and Allergy, University of Bonn, Bonn, GermanyDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany; Corresponding author.Background: The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a potential target for immune checkpoint inhibition immunotherapies. However, little is known about the biological and clinical significance of LAG3 DNA methylation in melanoma and its microenvironment. Methods: We evaluated LAG3 promoter and gene body methylation in a cohort of N = 470 melanoma patients obtained from The Cancer Genome Atlas (TCGA cohort), an independent cohort of N = 120 patients from the University Hospital Bonn, and in subsets of peripheral blood leukocytes, melanocytes, and melanoma cell lines. We validated the association of LAG3 methylation with mRNA expression in vitro in the melanoma cell line A375 treated with the hypomethylating agent 5-azacytidine and stimulated with interferon-γ. Finally, we investigated correlations between LAG3 methylation and progression-free survival in patients treated with immune checkpoint blockade (ICB cohort, N = 118). Findings: Depending on the analysed locus (promoter, gene body) we found region-dependent significant LAG3 methylation differences between monocytes, B cells, CD8+ and CD4+ T cells, regulatory T cells, melanocytes, and melanoma cell lines. In tumor tissues, methylation correlated significantly with LAG3 mRNA expression, immune cell infiltrates (histopathologic lymphocyte score and RNA-Seq signatures of distinct immune infiltrates), and an interferon-γ signature. Finally, LAG3 methylation was associated with overall survival in the TCGA cohort and progression-free survival in the ICB cohort. We detected basal LAG3 mRNA expression in the melanoma cell A375 and an interferon-γ inducible expression after demethylation with 5-azacytidine. Interpretation: Our study points towards an epigenetic regulation of LAG3 via promoter methylation and suggests a prognostic and predictive significance of LAG3 methylation in melanoma. Our results give insight in the tumor cell-intrinsic transcriptional regulation of LAG3 in melanoma. In perspective, our results might pave the way for investigating LAG3 methylation as a predictive biomarker for response to anti-LAG3 immune checkpoint blockage. Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.http://www.sciencedirect.com/science/article/pii/S2352396420303388LAG3DNA MethylationMelanomaPredictive BiomarkerImmunotherapy |